As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.
12 Analysts have issued a Kodiak Sciences, Inc. forecast:
12 Analysts have issued a Kodiak Sciences, Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -205 -205 |
10%
10%
|
|
| EBIT (Operating Income) EBIT | -223 -223 |
9%
9%
|
|
| Net Profit | -217 -217 |
13%
13%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
| Head office | United States |
| CEO | Victor Perlroth |
| Employees | 121 |
| Founded | 2009 |
| Website | kodiak.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


